ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.500,45
-0,54%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,53%
Euro vs US Dollar
1,08949
-0,04%
Bitcoin
63.200,62
-2,55%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Ardelyx Inc (ARDX)

  7. Ardelyx Inc (ARDX) News

ARDX

Ardelyx (ARDX)

Ardelyx Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ARDX
DatumZeitQuelleÜberschriftSymbolFirma
31/10/202312h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARDXArdelyx Inc
31/10/202312h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDXArdelyx Inc
31/10/202312h00GlobeNewswire Inc.Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue GuidanceNASDAQ:ARDXArdelyx Inc
30/10/202322h42GlobeNewswire Inc.Ardelyx, Inc. Reports Employment Inducement GrantsNASDAQ:ARDXArdelyx Inc
23/10/202314h07GlobeNewswire Inc.Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023NASDAQ:ARDXArdelyx Inc
18/10/202322h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDXArdelyx Inc
18/10/202322h02GlobeNewswire Inc.Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023NASDAQ:ARDXArdelyx Inc
18/10/202321h35AllPennyStocks.comBiotech Finds Mid-Week Success Following FDA AnnouncementNASDAQ:ARDXArdelyx Inc
18/10/202315h03IH Market NewsWednesday’s Wall Street Highlights: ASML, Nvidia, United Airlines, Viking Therapeutics, P&G, and MoreNASDAQ:ARDXArdelyx Inc
18/10/202314h30Dow Jones NewsArdelyx Shares Rally Premarket on FDA Approval of XphozahNASDAQ:ARDXArdelyx Inc
18/10/202301h44Dow Jones NewsArdelyx Gets FDA OK for Add-On Therapy for Kidney Disease PatientsNASDAQ:ARDXArdelyx Inc
18/10/202301h23GlobeNewswire Inc.Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed CapitalNASDAQ:ARDXArdelyx Inc
18/10/202301h01GlobeNewswire Inc.FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption InhibitorNASDAQ:ARDXArdelyx Inc
13/10/202314h00GlobeNewswire Inc.Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PANASDAQ:ARDXArdelyx Inc
12/10/202323h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDXArdelyx Inc
10/10/202322h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARDXArdelyx Inc
04/10/202314h00GlobeNewswire Inc.Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023NASDAQ:ARDXArdelyx Inc
28/09/202314h02GlobeNewswire Inc.Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and MotilityNASDAQ:ARDXArdelyx Inc
25/09/202323h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDXArdelyx Inc
25/09/202310h15GlobeNewswire Inc.Tenapanor for Hyperphosphatemia Approved in JapanNASDAQ:ARDXArdelyx Inc
12/09/202323h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDXArdelyx Inc
11/09/202314h00GlobeNewswire Inc.Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023NASDAQ:ARDXArdelyx Inc
08/09/202322h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARDXArdelyx Inc
08/09/202314h00GlobeNewswire Inc.Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ARDXArdelyx Inc
07/09/202314h00GlobeNewswire Inc.Ardelyx, Inc. Reports Employment Inducement GrantsNASDAQ:ARDXArdelyx Inc
23/08/202322h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDXArdelyx Inc
23/08/202322h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDXArdelyx Inc
23/08/202322h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDXArdelyx Inc
23/08/202322h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDXArdelyx Inc
23/08/202322h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDXArdelyx Inc
 Showing the most relevant articles for your search:NASDAQ:ARDX

Kürzlich von Ihnen besucht

LSE
46KB
Euro.bk.z Cpn07
BIT
P23HW4
NLBNPIT23HW4 20991231 27...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten